Calendar
FDA binigyan ng CPR Pfizer bivalent COVID-19 vaccine
BINIGYAN ng Food and Drug Administration (FDA) ng certificate of product registration (CPR) ang Pfizer bivalent COVID-19 vaccine.
Ang naturang rehistro ay kailangan upang maibenta ang naturang bakuna sa publiko.
“The FDA is pleased to announce the approval of the application and grant of CPR for Toziameran + Famtozinameran (15 mcg/15 mcg)/ 0.3 mL Dispersion for Injection with a brand name, Comirnaty Original/ Omicron B.A. 4-5,” sabi ng FDA.
“The FDA has granted the CPR with five years validity after a comprehensive evaluation process, extensive clinical trials, and thorough assessment of all available scientific data and information provided by the vaccine manufacturer and comprehensive evaluation process,” sabi pa ng FDA.
Ang bivalent vaccine ay sinasabing mas mabisa kumpara sa mga naunang bakunang inilabas laban sa COVID-19.
